Please login to the form below

Not currently logged in
Email:
Password:

volanesorsen

This page shows the latest volanesorsen news and features for those working in and with pharma, biotech and healthcare.

AZ adds another Ionis drug in $330m kidney disease deal

AZ adds another Ionis drug in $330m kidney disease deal

volanesorsen for familial chylomicronaemia syndrome and inotersen for TTR amyloidosis in late-stage development.

Latest news

  • Safety issues dampen enthusiasm for Akcea's volanesorsen Safety issues dampen enthusiasm for Akcea's volanesorsen

    Safety issues dampen enthusiasm for Akcea's volanesorsen. But Ionis Pharmaceuticals' subsidiary presses on with filing plans. ... Volanesorsen tackles the problem by reducing the production of a protein (ApoC-III) that is involved in the regulation of

  • Isis renamed Ionis to sidestep militant association Isis renamed Ionis to sidestep militant association

    IONIS-TTR Rx is being developed for familial amyloid polyneuropathy and amyloid cardiomyopathy in partnership with GlaxoSmithKline (GSK), while Biogen-partnered nusinersen is being tested in spinal muscular atrophy and volanesorsen

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics